Auteur E. W. GUNDERSON

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans

M. HANEY ; E. W. GUNDERSON ; H. JIANG ; E. D. COLLINS ; R. W. FOLTIN | 2010
Dans Biological Psychiatry (Vol.67, n°1, January 2010) Article : Périodique

BACKGROUND. Rates of relapse among cocaine-dependent patients are high, and new treatment approaches are needed. Clinical data demonstrate that a cocaine vaccine (TA-CD) produces selective anticocaine antibodies, yet the impact of these antibodi[...]

Plus d'info

Ajouter à la sélection

Designer drugs 2015: Assessment and management

M. WEAVER ; J. HOPPER ; E. W. GUNDERSON | 2015
Dans Addiction Science and Clinical Practice (Vol.10, n°8, March 2015) Article : Périodique

Recent designer drugs, also known as "legal highs," include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as "bath salts"); synthetic cannabinoids (SCs; e.g., Spice); and synthetic halluci[...]

Plus d'info

Ajouter à la sélection

Lien externe

Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep

M. HANEY ; E. W. GUNDERSON ; RABKIN J. ; C. L. HART ; S. K. VOSBURG ; S. D. COMER ; R. W. FOLTIN | 2007
Périodique

ENGLISH : OBJECTIVES: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral dronabinol maintenance in HIV-p[...]

Plus d'info

Ajouter à la sélection

"Spice" and "K2" herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans

E. W. GUNDERSON ; H. M. HAUGHEY ; N. AIT-DAOUD ; A. S. JOSHI ; C. L. HART | 2012
Dans American Journal on Addictions (Vol.21, n°4, July-August 2012) Article : Périodique

Cannabis, the most commonly used illicit substance, exerts its primary psychoactive effect via delta-9 tetrahydrocannabinol (Δ9-THC) agonism of cannabinoid receptor type 1 (CB1). Some users develop a cannabis use disorder and physical dependence[...]

Plus d'info

Ajouter à la sélection

Substituted cathinone products: A new trend in "bath salts" and other designer stimulant drug use

E. W. GUNDERSON ; M. G. KIRKPATRICK ; L. M. WILLING ; C. P. HOLSTEGE | 2013
Dans Journal of Addiction Medicine (Vol.7, n°3, May-June 2013) Article : Périodique

There is a growing concern about the availability of a new generation of "designer drug" stimulants that are marketed as "bath salts" and other household products. The products are not true bath salts and contain substituted cathinone stimulant [...]

Plus d'info

Ajouter à la sélection

A survey of synthetic cannabinoid consumption by current cannabis users

E. W. GUNDERSON ; H. M. HAUGHEY ; N. AIT-DAOUD ; A. S. JOSHI ; C. L. HART | 2014
Dans Substance Abuse (Vol.35, n°2, 2014) Article : Périodique

Background: Despite growing concern about the increased rates of synthetic cannabinoid (SC) use and their effects, only limited data are available that addresses these issues. This study assessed the extent of SC product use and reported effects[...]

Plus d'info

Ajouter à la sélection

Synthetic cannabinoids: a new frontier of designer drugs

E. W. GUNDERSON | 2013
Dans Annals of Internal Medicine (Vol.159, n°8, 15 October 2013) Article : Périodique

Plus d'info

Ajouter à la sélection